In this study, untargeted metabolomic analysis suggests that TRPML1 inhibition in cisplatin-resistant ovarian cancer cells induces alterations in metabolites associated with arginine and other amino acid metabolisms. Here, MCOLN1 is linked to ovarian carcinoma.